logo-loader
viewBioLargo, Inc.

BioLargo subsidiary receives FDA clearance to market Clyra Wound Irrigation Solution

The product is designed for cleansing, irrigating, and debriding dermal wounds and burns

BioLargo - BioLargo Inc subsidiary Clyra Medical Technologies receives 510(k) clearance from US Food and Drug Administration to market its Clyra Wound Irrigation Solution
BioLargo said the wound solution is the first of several products that will feature its platform antimicrobial technology

BioLargo Inc (OTCMKTS:BLGO) subsidiary Clyra Medical Technologies has received 510(k) clearance from the US Food and Drug Administration to market its Clyra Wound Irrigation Solution, the environmental engineering company said Monday. 

The product is designed for cleansing, irrigating, and debriding dermal wounds and burns, in addition to moistening and lubricating absorbent wound dressings. 

BioLargo said the wound solution is the first of several products that will feature the company’s platform antimicrobial technology, which provides sustained antimicrobial efficacy (including biofilm) without causing harm to the tissue.

READ: BioLargo boosts revenue, cuts loss in 2Q

“This is a pivotal milestone in our mission to build a world-class portfolio of unique products and solutions to help heal patients," said Clyra President Steve Harrison in a statement.

“This FDA clearance is a critical step in the development of our product portfolio and the execution of our commercial strategy. Next up are clinical trials for high-value applications for this platform product.”

BioLargo CEO Dennis Calvert added that the FDA decision “illustrates our dedication to carry high-impact technology solutions from concept to completion as we strive to solve pressing issues affecting countless people across the planet.”

The company, based in Westminster, California, has developed several innovative and patented products targeted at three markets: water and wastewater treatment, industrial odor and volatile organic compounds (VOC) elimination, and advanced wound care. 

BioLargo’s stock recently traded 2.5% higher to $0.23 a share on the OTC Market. 

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

Quick facts: BioLargo, Inc.

Price: 0.1722 USD

OTCMKTS:BLGO
Market: OTCQB
Market Cap: $28.23 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of BioLargo, Inc. named herein, including the promotion by the Company of BioLargo, Inc. in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: BioLargo announces joint venture with BKT and Tomorrow Water...

BioLargo (OTCQB: BLGO) CEO Dennis Calvert joined Steve Darling from Proactive in Vancouver to discuss the company finalizing their deal with BKT and Tomorrow Water in South Korea.  Calvert discusses what this deal provides Bio Largo and also about the recent announcement about their...

2 weeks, 2 days ago

2 min read